Lumos Advances FebriDx® Sales with iMedical Purchase Order
14 May 2025
Lumos has today announced that it has received and shipped a purchase order for FebriDx® from iMedical, Inc. for US$126,000, representing its largest single purchase order since the test's launch.
iMedical is a leader in developing and delivering innovative cost-savings solutions tailored for hospitals, surgery centers, clinics, and healthcare facilities nationwide across the US. This significant order signals increasing US customer adoption and continued market acceptance of our novel point-of-care test.
Lumos CEO & MD, Doug Ward commented:
"I'm pleased to see FebriDx gaining traction and acceptance in the market. It's a testament to the product’s clinical value and growing demand. Lumos looks forward to working more closely with iMedical to expand FebriDx’s market acceptance and adoption."
Click to read the ASX Release.
iMedical is a leader in developing and delivering innovative cost-savings solutions tailored for hospitals, surgery centers, clinics, and healthcare facilities nationwide across the US. This significant order signals increasing US customer adoption and continued market acceptance of our novel point-of-care test.
Lumos CEO & MD, Doug Ward commented:
"I'm pleased to see FebriDx gaining traction and acceptance in the market. It's a testament to the product’s clinical value and growing demand. Lumos looks forward to working more closely with iMedical to expand FebriDx’s market acceptance and adoption."
Click to read the ASX Release.
